戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 transported to cytosol and incorporated into argininosuccinate.
2 ed with l-citrulline increased the levels of argininosuccinate, an enzyme that metabolizes l-citrulli
3 tained unchanged during the evolution of the argininosuccinate gene are able to change in the pseudog
4                With constitutively expressed argininosuccinate lyase (AL), AS confers cells with an A
5 zymes, argininosuccinate synthetase (AS) and argininosuccinate lyase (AL).
6                        The urea cycle enzyme argininosuccinate lyase (ASL) enables the clearance of n
7                                              Argininosuccinate lyase (ASL) is required for the synthe
8                                              Argininosuccinate lyase (ASL) is the only mammalian enzy
9                                              Argininosuccinate lyase (ASL) is the only mammalian enzy
10  urea cycle disorder caused by deficiency of argininosuccinate lyase (ASL) with a wide clinical spect
11 zed by argininosuccinate synthase (Ass1) and argininosuccinate lyase (Asl), which would lead to abund
12    We show that a hypomorphic mouse model of argininosuccinate lyase (encoded by Asl) deficiency has
13 uals with argininosuccinate synthetase 1 and argininosuccinate lyase deficiencies identified by newbo
14 inate synthetase deficiency (0.22 +/- 0.03), argininosuccinate lyase deficiency (0.35 +/- 0.11), and
15 dge, this is the first report of an acquired argininosuccinate lyase deficiency by liver transplantat
16 inosuccinate synthetase mRNA but did express argininosuccinate lyase mRNA, suggesting that the argini
17 tures in the fumarase superfamily, including argininosuccinate lyase, delta-crystallin, fumarase, and
18 Together, these three enzymes, eNOS, AS, and argininosuccinate lyase, make up the citrulline-NO cycle
19 re identified as argininosuccinate synthase, argininosuccinate lyase, neuronal nitric-oxide synthase,
20 accharomyces cerevisiae counterparts, namely argininosuccinate lyase, PR-aminoimidazolesuccinocarboxa
21 enzymes, argininosuccinate synthase (AS) and argininosuccinate lyase, providing the substrate arginin
22  suppressed pyrimidine biosynthetic pathway, argininosuccinate lyase-encoding, and ABC transporter-re
23 wo steps by argininosuccinate synthetase and argininosuccinate lyase.
24 SL gene, which encodes the urea cycle enzyme argininosuccinate lyase.
25 ing enzymes argininosuccinate synthetase and argininosuccinate lyase.
26 cing, we show that an inflammatory aspartate-argininosuccinate shunt is induced following lipopolysac
27 ne is recycled to l-arginine by two enzymes, argininosuccinate synthase (AS) and argininosuccinate ly
28                                              Argininosuccinate synthase (AS) catalyzes the rate-limit
29                                              Argininosuccinate synthase (AS) is a ubiquitous enzyme i
30              Based on the integral role that argininosuccinate synthase (AS) plays in the production
31 used to selectively reduce the expression of argininosuccinate synthase (AS), because the only known
32 pression of the arginine resynthesis enzymes argininosuccinate synthase (ASS) and ornithine transcarb
33                                              Argininosuccinate synthase (ASS) is the rate-limiting en
34 ught to fuel arginine synthesis catalyzed by argininosuccinate synthase (Ass1) and argininosuccinate
35 is pathway associated with overexpression of argininosuccinate synthase (ASS1) and arginosuccinate ly
36  or miR-1291) may modulate the expression of argininosuccinate synthase (ASS1) and glucose transporte
37      Downregulation of the urea cycle enzyme argininosuccinate synthase (ASS1) by either promoter met
38            The shunt, supported by increased argininosuccinate synthase (ASS1) expression, also leads
39                                              Argininosuccinate synthase (ASS1) is a urea cycle enzyme
40 , CLOCK directly acetylates K165 and K176 of argininosuccinate synthase (ASS1) to inactivate ASS1, wh
41 , we identify the epigenetic reactivation of argininosuccinate synthase (ASS1), a urea cycle enzyme s
42                                              Argininosuccinate synthase 1 (ASS1) serves as a critical
43 gen efflux by upregulating the expression of argininosuccinate synthase 1 (ASS1), a key enzyme in the
44   Multiple KSHV-encoded microRNAs upregulate argininosuccinate synthase 1 (ASS1), a key enzyme in the
45 els for phosphoenolpyruvate carboxykinase 1, argininosuccinate synthase 1, sodium/glucose co-transpor
46 es in the arginine-recycling pathway enzymes argininosuccinate synthase and ornithine transcarbamylas
47 0461) of H. influenzae, the gene encoding an argininosuccinate synthase homolog, and a change in the
48 ucocorticoid-induced leucine zipper protein, argininosuccinate synthase, and human prostaglandin tran
49 ven up-regulated proteins were identified as argininosuccinate synthase, argininosuccinate lyase, neu
50 e (AUC) for cytoplasmic aconitate hydratase, argininosuccinate synthase, carbamoylphosphate synthase,
51 also inhibited cytokine induction in CMEC of argininosuccinate synthase, the rate-limiting enzyme for
52       Given the different roles ascribed for argininosuccinate synthase, urea versus NO production, t
53 ic carcinoma cells through the regulation of argininosuccinate synthase- and glucose transporter prot
54 quires the sequential action of two enzymes, argininosuccinate synthetase (AS) and argininosuccinate
55 anomas and other cancers that do not express argininosuccinate synthetase (AS), the rate-limiting enz
56  inducible isoform of NO synthase (iNOS) and argininosuccinate synthetase (AS).
57 acy of ADI-PEG20 is directly correlated with argininosuccinate synthetase (ASS) deficiency.
58 ted urea cycle disorder that is caused by an argininosuccinate synthetase (ASS) enzyme deficiency.
59 gh energy demand, the ornithine cycle enzyme argininosuccinate synthetase (ASS) is a principle site o
60 nous arginine is required for growth in some argininosuccinate synthetase (ASS)-deficient cancers.
61 two-hybrid screening of PRMT7 and identified argininosuccinate synthetase (ASS1) as a potential inter
62                              The latter lack argininosuccinate synthetase (ASS1) making them auxotrop
63 ed to influence HSV-1 replication, including argininosuccinate synthetase 1 (AS1), which consumes asp
64  20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors b
65 s study, we focused on the urea cycle enzyme argininosuccinate synthetase 1 (ASS1) as a therapeutic t
66 ynthesis of arginine (Arg) as the key enzyme argininosuccinate synthetase 1 (ASS1) is silenced.
67                                              Argininosuccinate synthetase 1 (ASS1) is the key enzyme
68                                      Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for
69 inine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers,
70       It is noteworthy that individuals with argininosuccinate synthetase 1 and argininosuccinate lya
71            In ornithine transcarbamylase and argininosuccinate synthetase 1 deficiencies, we did not
72 on-arginine-auxotrophic cellular background (argininosuccinate synthetase 1 positive).
73 ot only enhanced the cellular sensitivity of argininosuccinate synthetase 1-positive GBM to ionizing
74  synthesized from citrulline in two steps by argininosuccinate synthetase and argininosuccinate lyase
75 he citrulline to arginine converting enzymes argininosuccinate synthetase and argininosuccinate lyase
76 le metabolism characterized by deficiency of argininosuccinate synthetase and consequent life-threate
77           Because of decreased expression of argininosuccinate synthetase and/or ornithine transcarba
78 fected with an expression plasmid containing argininosuccinate synthetase cDNA.
79 uished asymptomatic heterozygous carriers of argininosuccinate synthetase deficiency (0.22 +/- 0.03),
80 cinoma (HCC) is an arginine auxotroph due to argininosuccinate synthetase I deficiency.
81 of melanoma and HCC is due to the absence of argininosuccinate synthetase in these cells and that an
82 cient Spf(ash) mouse and the neonatal lethal argininosuccinate synthetase knockout mouse.
83           Melanomas and HCCs did not express argininosuccinate synthetase mRNA but did express argini
84 1-deleted adenoviral vector expressing human argininosuccinate synthetase resulted in transduction of
85                                              Argininosuccinate synthetase, a key enzyme in the metabo
86 loid leukemias (AMLs) have low expression of argininosuccinate synthetase-1 (ASS1), rendering AML cel
87 ical enzyme required for arginine synthesis, argininosuccinate synthetase-1 (ASS1).
88 ells was a result of an inability to produce argininosuccinate synthetase.
89                           We sequenced three argininosuccinate-synthetase-processed pseudogenes (PsiA